A Study to Evaluate the Effectiveness and Safety of Prophylactic Emicizumab Versus no Prophylaxis in Haemophilia A Patients Without Inhibitors

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

•To evaluate the efficacy of prophylactic emicizumab (1.5 mg/kg/week or 3 mg/kg/2weeks) compared with no prophylaxis in patients with haemophilia A without FVIII inhibitors on the basis of the number of bleeds over time

Critère d'inclusion

Haemophilia A without factor VIII inhibitors